Haemonetics Corporation (HAE)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 988 | 870 | 993 | 1,169 | 1,309 | 1,361 | 1,334 | 1,352 |
| Operating profit | $m | 241 | 246 | ||||||
| Net profit | $m | 77 | 79 | 43 | 115 | 118 | 168 | 97 | 96 |
| EPS reported | $ | 2.05 | 2.04 | ||||||
| Operating cashflow per share | $ | 6.22 | 7.23 | ||||||
| Capex per share | $ | 0.69 | 0.81 | ||||||
| FCF per share | $ | 5.52 | 6.42 | ||||||
| Free cash flow | $m | 260 | 291 | ||||||
| Net debt | $m | 979 | 951 | ||||||
| Book value equity | $m | 796 | 837 | ||||||
| Book value per share | $ | 16.82 | 18.32 | ||||||
| Number of shares | m | 47.35 | 45.7 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 19.83 | 51.62 | ||||||
| P/B LTM | x | 3.20 | 3.80 | ||||||
| P/S LTM | x | 3.38 | 2.35 | ||||||
| P/FCF LTM | x | 9.79 | 10.92 | ||||||
| EV/EBITDA LTM | x | 7.25 | 15.69 | ||||||
| EV/Sales LTM | x | 2.49 | 3.76 | ||||||
| Earnings Yield LTM | % | +9.83% | +1.94% | ||||||
| FCF Yield | % | +10.22% | +9.16% | ||||||
| Quality | |||||||||
| ROE | % | +12.22% | +11.35% | ||||||
| ROIC | % | +8.66% | +8.61% | ||||||
| Operating margin | % | +18.10% | +18.18% | ||||||
| Gross margin | % | +55.74% | +57.38% | ||||||
| FCF/Sales | % | +19.52% | +21.54% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -38.07% | -10.92% | ||||||
| Sales Growth YoY | % | -1.97% | +3.28% | ||||||
| Net Income Growth YoY | % | -41.97% | -18.09% | ||||||
| FCF Growth | % | +82.83% | +102.76% | ||||||
| Operating Profit Growth | % | +8.83% | +49.04% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.21 | 0.25 | ||||||
| Net Debt/EBITDA | x | 3.13 | 3.64 | ||||||
| EBIT/Net interest | x | 8.41 | 8.03 | ||||||
| Net debt/market cap | % | +48.03% | +28.45% | ||||||
| Net debt/Equity | x | 1.23 | 1.14 | ||||||
| Gross debt/equity | x | 1.54 | 1.40 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free